Holen Sie sich die Stockscreener-App
4.43
5.34%
-0.25
Vorhandelsmarkt:
4.54
0.11
+2.48%
Schlusskurs vom Vortag:
$4.68
Offen:
$4.6
24-Stunden-Volumen:
1.22M
Relative Volume:
0.95
Marktkapitalisierung:
$288.22M
Einnahmen:
$297.18M
Nettoeinkommen (Verlust:
$-51.64M
KGV:
-5.5148
EPS:
-0.8033
Netto-Cashflow:
$-50.72M
1W Leistung:
-9.78%
1M Leistung:
+3.02%
6M Leistung:
-27.26%
1J Leistung:
-65.92%
1-Tages-Spanne:
$4.40
$4.635
1-Wochen-Bereich:
$4.40
$4.91
52-Wochen-Spanne:
$4.0913
$13.10
Evolus Inc Stock (EOLS) Company Profile
Firmenname
Evolus Inc
Sektor
Telefon
(949) 284-4555
Adresse
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Compare EOLS vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
4.43 | 288.22M | 297.18M | -51.64M | -50.72M | -0.8033 |
TAK
Takeda Pharmaceutical Co Adr
|
18.04 | 56.99B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
115.93 | 48.94B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.30B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.14 | 33.94B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
531.82 | 23.31B | 3.18B | 1.33B | 1.04B | 27.90 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-06 | Herabstufung | Needham | Buy → Hold |
| 2025-04-17 | Eingeleitet | BTIG Research | Buy |
| 2024-01-29 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-06-23 | Eingeleitet | Needham | Buy |
| 2022-05-12 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-01-20 | Hochstufung | Truist | Hold → Buy |
| 2021-05-06 | Hochstufung | Mizuho | Neutral → Buy |
| 2021-04-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-02-24 | Herabstufung | Truist | Buy → Hold |
| 2020-07-07 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-02-06 | Fortgesetzt | Mizuho | Buy |
| 2019-11-26 | Eingeleitet | SVB Leerink | Outperform |
| 2019-09-05 | Fortgesetzt | Mizuho | Buy |
| 2019-06-28 | Eingeleitet | Wells Fargo | Market Perform |
| 2019-06-11 | Eingeleitet | Barclays | Underweight |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2019-02-14 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-01-29 | Eingeleitet | Stifel | Buy |
Alle ansehen
Evolus Inc Aktie (EOLS) Neueste Nachrichten
Evolus, Inc.(NasdaqGM: EOLS) dropped from S&P Pharmaceuticals Select Industry Index - marketscreener.com
Evolus (NASDAQ:EOLS) Insider David Moatazedi Sells 13,669 Shares - MarketBeat
Evolus (NASDAQ:EOLS) Insider Rui Avelar Sells 3,119 Shares - MarketBeat
Avelar Rui sells Evolus (EOLS) shares worth $14815 By Investing.com - Investing.com Canada
Evolus CEO Moatazedi sells $64929 in shares - Investing.com
Avelar Rui sells Evolus (EOLS) shares worth $14815 - Investing.com
Evolus (EOLS) officer tax-driven sale of 3,119 shares under 10b5-1 plan - Stock Titan
Evolus (NASDAQ: EOLS) insider sells 13,669 shares to cover taxes - Stock Titan
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Evolus CEO Moatazedi sells $570k in shares By Investing.com - Investing.com India
Insider Selling: Evolus (NASDAQ:EOLS) Insider Sells 29,996 Shares of Stock - MarketBeat
David Moatazedi Sells 116,720 Shares of Evolus (NASDAQ:EOLS) Stock - MarketBeat
Avelar Rui, chief medical officer at Evolus, sells $146k in EOLS stock By Investing.com - Investing.com Australia
Avelar Rui, chief medical officer at Evolus, sells $146k in EOLS stock - Investing.com Australia
Evolus CEO Moatazedi sells $570k in shares - Investing.com
Evolus (EOLS) executive sells 29,996 shares after PSU vesting - Stock Titan
(EOLS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Dip Buying: What is the earnings history of Evolus IncMarket Sentiment Review & Safe Entry Point Identification - baoquankhu1.vn
Evolus plunges after Q2 miss, guidance cut; Needham downgrades - MSN
Jobs Data: Whats the beta of Evolus Inc stockTrade Entry Summary & Fast Momentum Entry Tips - baoquankhu1.vn
Divisadero Street Capital Management LP Makes New $2.38 Million Investment in Evolus, Inc. $EOLS - MarketBeat
Evolus Sees Toxin Market Stabilizing, Evolysse Gaining Traction, Raises 2028 Revenue Targets at Conference - Yahoo Finance
Evolus (NASDAQ:EOLS) Rating Lowered to "Hold" at Wall Street Zen - MarketBeat
Evolus, Inc. Files Form 8-K Announcing Executive Changes and Company Information (March 13, 2026) - Minichart
Evolus reclassifies Vikram Malik to Class II director to balance board - Investing.com
Evolus reclassifies Vikram Malik to Class II director to balance board By Investing.com - Investing.com UK
Vikram Malik reclassified to Class II director at Evolus - TradingView
Evolus (EOLS) reclassifies chairman Vikram Malik to restore board balance - Stock Titan
Evolus, Inc. Announces Executive Changes, Effective March 13, 2026 - marketscreener.com
How The Narrative On Evolus (EOLS) Is Resetting After Cautious 2025 And 2026 Guidance - Yahoo Finance
Evolus at Leerink Global Healthcare Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
New Highs: What is the earnings history of Evolus IncMarket Growth Review & High Win Rate Trade Tips - baoquankhu1.vn
Evolus Earnings Call Signals Growth Amid Headwinds - The Globe and Mail
Evolus, Inc. (NASDAQ:EOLS) Q4 2025 earnings call transcript - MSN
Market Outlook: What analysts say about Evolus Inc stockTrade Ideas & Short-Term High Return Strategies - baoquankhu1.vn
Bank Watch: Can Evolus Inc navigate macro headwindsPortfolio Growth Summary & Weekly Watchlist of Top Performers - baoquankhu1.vn
(EOLS) Risk Channels and Responsive Allocation - Stock Traders Daily
Can Evolus Inc. stock maintain growth trajectoryChart Signals & Community Consensus Trade Alerts - Naître et grandir
Evolus (NASDAQ:EOLS) Rating Increased to Buy at Wall Street Zen - MarketBeat
Why Evolus Stock Soared Today - AOL.com
Evolus, Inc. (EOLS) matches Q4 earnings estimates - MSN
Evolus, Inc. (NASDAQ:EOLS) Q4 2025 Earnings Call Transcript - Insider Monkey
Analysts Are Bullish on These Healthcare Stocks: Evolus (EOLS), Aldeyra Therapeutics (ALDX) - The Globe and Mail
Data Privacy Compliance Risks Threaten Evolus’s Operations and Financial Health - TipRanks
BTIG Reiterates Buy Rating for Evolus (EOLS) with $13 Target | E - GuruFocus
Evolus (EOLS) Nears Breakeven In Q4 EPS Challenging Prolonged Loss Narratives - simplywall.st
Evolus Q4 2025 slides: revenue growth continues despite forecast miss - Investing.com Australia
EOLS SEC FilingsEvolus 10-K, 10-Q, 8-K Forms - Stock Titan
Evolus posts record rally after Q4 beat (EOLS:NASDAQ) - Seeking Alpha
Midday Stock Roundup: Evolus, Xponential up - Orange County Business Journal
Evolus Up Over 26%, on Pace for Largest Percent Increase Since January 2025 -- Data Talk - 富途牛牛
Finanzdaten der Evolus Inc-Aktie (EOLS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.75%
1.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):